

FORM PTO-159

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:  
CV01378KSERIAL NO.:  
10/057,534INFORMATION DISCLOSURE STATEMENT  
BY APPLICANTAPPLICANT:  
Harry R. Davis et al.

(Use several sheets if necessary)

FILING DATE:  
January 25, 2002GROUP:  
1615

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA					
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AL					
	AM					
	AN					
	AO					
	AP					

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

✓	AQ	Luis Gruberg, MD, Inflammatory Markers in Acute Coronary Syndromes: C-reactive Protein (CRP) and Chlamydia, American Heart Association Scientific Sessions 2000
	AR	
	AS	
	AT	
	AU	
	AV	

EXAMINER

DATE CONSIDERED

S. V. D

10/10/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



RECEIVED  
JUN 04 2003  
TECH CENTER 1400/251  
JUN 04 2003

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.:

CV01378K

SERIAL NO.:

10/057,534

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(Use several sheets if necessary)

APPLICANT:

Harry R. Davis et al.

FILING DATE:

January 25, 2002

GROUP:

1615

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES	NO
SW	AL	WO 95/35277A	12/28/95	PCT				
	AM	WO 02/50068A	06/27/02	PCT				
	AN	WO 02/50060A	06/27/02	PCT				
SW	AO	WO 02/50027A	06/27/02	PCT				
	AP							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AQ	
	AR	
	AS	
	AT	
	AU	
	AV	

EXAMINER

S-C ✓

DATE CONSIDERED

10/10/02

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



P.T.O. 1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.:

CV01378K

SERIAL NO.:

10/057,534

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

APPLICANT:

Harry R. Davis, et al.

FILING DATE:

January 25, 2002

GROUP:

1615

(Use several sheets if necessary)

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


AA	<b>Exhibit A:</b> SCH 58235 Micronized (ezetimibe), Drug Formulation Development Summary
AB	<b>Exhibit B:</b> SCH 58235 (ezetimibe), Drug Formulation Development Summary
AC	<b>Exhibit C:</b> SCH 58235 (ezetimibe), Drug Formulation Development Summary
AD	<b>Exhibit D:</b> SCH 58235 (ezetimibe), Drug Formulation Development Summary
AE	<b>Exhibit E:</b> SCH 58235 (ezetimibe), Drug Formulation Development Summary
AF	<b>Exhibit F:</b> SCH 58235 (ezetimibe), Drug Formulation Development Summary
AG	<b>Exhibit G:</b> SCH 58235 (ezetimibe), Drug Formulation Development Summary
AH	<b>Exhibit H:</b> SCH 58235 (ezetimibe), Drug Formulation Development Summary
AI	<b>Exhibit 1:</b> Master Sheet for the SCH 58235 and Lovastatin Research Study, <i>Schering-Plough Research Institute</i> (Protocol No. C906-411), page 1576-1585
AJ	<b>Exhibit 2:</b> Medical Research Study #1055/97, SCH 58235: Bioavailability of Single Oral Doses of Two Prototype Tablet Formulations and the Reference Capsule Formulation of SCH 58235 in Normal Male Volunteers: A Four Way Crossover Study #C97-221-01, Informed Consent, <i>Peninsular Testing Corporation</i> , page 106-112
AK	<b>Exhibit 3:</b> Consent Form to Participate in a Research Study, "A Phase II Double Blind Dose Response Investigation of Efficacy and Safety of Four Doses of SCH 58235 Compared to Placebo in Subjects with Primary Hypercholesterolemia," <i>Schering-Plough Research Institute</i> (Protocol No. C98-010), page 1558-1566
AL	<b>Exhibit 4:</b> Medical Research Study #1096/99, SCH 58235: Pharmacokinetic Pharmacodynamic Drug Interaction Study with Digoxin in Healthy Volunteers #C98-114, Informed Consent, <i>Peninsular Testing Corporation</i> , page 124-130
AM	<b>Exhibit 5:</b> Informed Consent, "SCH 58235: Assessment of Multiple-Dose Drug Interaction Between 58235 and Gemfibrozil in Healthy Volunteers," <i>Schering-Plough Research Institute</i> , page 1-8

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED  
MAY 07 2003  
TECH CENTER 1600/2900



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:  
CV01378KSERIAL NO.:  
10/057,534INFORMATION DISCLOSURE STATEMENT  
BY APPLICANTAPPLICANT:  
Harry R. Davis et al.FILING DATE:  
January 25, 2002GROUP:  
1615

(Use several sheets if necessary)

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
sm	AA	US2002/0132855	09/19/02	Nelson, et al.			
	AB	US2002/0137689	09/26/02	Glombik et al.			
	AC	US2002/0128253	09/12/02	Glombik et al.			
	AD	US2002/0039774	04/04/02	Kramer et al.			
	AE	US2002/0128252	09/12/02	Glombik et al.			
	AG	10/057,646	01/25/02	Harry R. Davis et al.			
	AH	10/057,629	01/25/02	Harry R. Davis			
	AI	10/154,106	05/22/02	Harry R. Davis et al.			
	AJ	10/057,323	01/25/02	Harry R. Davis et al.			
	AK	10/136,968	05/01/02	Wing-Kee Philip Cho et al.			
	AL	10/057,339	01/25/02	Teddy Kosoglou et al.			
	AM	10/247,032	01/25/02	Harry R. Davis			
	AN	10/056,680	01/25/02	Teddy Kosoglou et al.			
	AO	10/247,099	09/19/02	Harry R. Davis et al.			
	AP	10/247,085	09/19/02	John T. Strony			
	AQ	10/247,095	09/19/02	Harry R. Davis			
	AR	10/246,996	09/19/02	Alexandre P. Lebeaut et al.			
	AS	10/247,397	09/19/02	Harry R. Davis et al.			
sm	AT	10/166,942	06/11/02	Anima Ghosal et al.			

RECEIVED  
JAN 28 2003  
TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
sm	AU	BE 884722 A	12/01/80	BELGIUM	C07D	AG1K	X(abs.)	
	AV	CA 2253769	11/29/99	CANADA	A61K	31/22		
	AW	DE 2046823 A	03/30/72	GERMANY	C07C		X(abs.)	
	AX	DE 2521113 A	03/18/76	GERMANY	C07C	87/34	X(abs.)	
	AY	EP 0002151 A1,B1	05/30/79	EUROPE	C07C	69/67		
	AZ	EP 0010299 B1	02/15/84	EUROPE	A61K	45/06		
	BA	EP 0179559 A2	04/30/86	EUROPE	C07D	405/06		
	BB	EP 0199630 A1	10/29/86	EUROPE	C07D	205/08		
	BC	EP 0199630 B1	09/19/90	EUROPE	C07D	205/08		
	BD	EP 0264231 A1	04/20/88	EUROPE	C07D	205/08		
	BE	EP 0266896 B1	05/11/88	EUROPE	C07D	471/04		
	BF	EP 0274873 B1	07/20/88	EUROPE	C07K	11/00		
	✓ BG	EP 0288973 B1	11/02/88	EUROPE	C07D	417/06		
	✓ BH	EP 0311366 B1	04/12/89	EUROPE	C07D	471/04		
	✓ BI	EP 0333268 A1	09/20/89	EUROPE	C07F	7/18		
	✓ BJ	EP 0337549 A1	10/18/89	EUROPE	C07D	205/08		
	✓ BK	EP 0337549 B1	10/04/95	EUROPE	C07D	205/08		
	✓ BL	EP 0365364 A2	04/25/90	EUROPE	C07D	205/08		
	✓ BM	EP 0369686 A1	05/23/90	EUROPE	C07D	463/00		
	✓ BN	EP 0375527 A1	06/27/90	EUROPE	C07D	205/08	X(abs.)	
	✓ BO	EP 0401705 A3	12/12/90	EUROPE	A61K	31/66		
	✓ BP	EP 0415487 A2	03/06/91	EUROPE	C07D	205/08		
	BQ	EP 0455042 A1	11/06/91	EUROPE	A61K	31/19		
	BR	EP 0457514 A1	11/21/91	EUROPE	A61K	45/06		
	BS	EP 0457514 B1	08/21/96	EUROPE	A61K	45/06		
	BT	EP 0461548 A3	12/18/91	EUROPE	A61K	31/365		
sm	BU	EP 0462667 A2	12/27/91	EUROPE	C07D	205/08		

S. V. 6 10/10/03

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:  
CV01378KSERIAL NO.:  
10/057,538INFORMATION DISCLOSURE STATEMENT  
BY APPLICANTAPPLICANT:  
Harry R. Davis et al.FILING DATE:  
January 25, 2002GROUP:  
1615

(Use several sheets if necessary)

✓	AV	EP 0475148 A1	03/18/92	EUROPE	A61K	31/215		
	BW	EP 0475755 B1	03/18/92	EUROPE	C07D	403/06		
	BX	EP 0481671 A1	04/22/92	EUROPE	C07D	205/08		
	BY	EP 0482498 A3	04/29/92	EUROPE	A61K	31/66		
	BZ	EP 0524595 A1	01/27/93	EUROPE	C07D	205/08		
✓	CA	EP 0720599 B1	07/10/96	EUROPE	C07D	205/08		
	CB	EP 0793958 A2	09/10/97	EUROPE	A61K	9/16	X(abs.)	
✓	CC	EP 0814080 A1	12/29/97	EUROPE	C07D	267/14		
	CD	EP 0904781 A2	03/31/99	EUROPE	A61K	31/215		
	CE	EP 1048295 A2	11/02/00	EUROPE	A61K	31/216		
	CF	FR 1103113	10/31/55	FRANCE				X
	CG	FR 2779347	12/10/97	FRANCE	A61	031/215	X(abs.)	
	CH	GB 861367	02/22/61	GB	A61K			
	CI	GB 902658	08/09/62	GB	C07D			
✓	CJ	GB 1415295	11/26/75	GB	C07C	59/26		
✓	CK	GB 2329334 A	03/24/99	GB	A61K	45/00		
	CL	JP 028057	10/01/81	JAPAN			X(abs.)	
	CM	JP 121479	12/10/86	JAPAN			X(abs.)	
	CN	JP 136485	05/26/81	JAPAN			X(abs.)	
	CO	JP 180212	03/24/86	JAPAN			X(abs.)	
	CP	JP 219681	04/14/87	JAPAN			X(abs.)	
	CQ	JP 5194209 A	08/03/93	JAPAN	A61K	031/22	X(abs.)	
	CR	JP 5239020 A	1993	JAPAN	C07D	205/08	X(abs.)	
	CS	JP 4054182 A	1992	JAPAN	C12P	017/16	X(abs.)	
	CT	JP 63017859 A	1988	JAPAN	C07D	205/08	X(abs.)	
	CU	JP 4266869 A	1992	JAPAN	C07D	205/08	X(abs.)	
	CV	JP 4356195 A	1993	JAPAN			X(abs.)	
	CW	JP 4356495	12/10/92	JAPAN			X(abs.)	
	CX	JP 5058993 A	1993	JAPAN			X(abs.)	
	CY	JP 61280295 A	1987	JAPAN			X(abs.)	
	CZ	JP 95051558 B2	06/05/95	JAPAN	C07D	205/08	X(abs.)	
	DA	JP 91068020	10/25/91	JAPAN	C07D	205/08	X(abs.)	
	DB	JP 94047573	06/22/94	JAPAN	C07D	205/08	X(abs.)	
✓	DC	WO 82/01649	05/27/82	PCT	A61K	9/52	X(abs.)	
✓	DD	WO 87/04429	07/30/87	PCT	C07D	205/08		
✓	DE	WO 88/04656	06/30/88	PCT	C07D	405/04		
✓	DF	WO 88/05296	07/28/88	PCT	A61K	31/365		
✓	DG	WO 91/03249	03/21/91	PCT	A61K	31/785	X(abs.)	
✓	DH	WO 92/13837	08/20/92	PCT	C07D	205/085		
✓	DI	WO 93/02048	02/04/93	PCT	C07D	205/08		
✓	DJ	WO 93/07167	04/15/93	PCT	C07J	71/00		
✓	DK	WO 93/11150	06/10/93	PCT	C07J	71/00		
✓	DL	WO 94/00480	01/06/94	PCT	C07J	71/00		
✓	DM	WO 94/14433	07/07/94	PCT	A61K	31/395		
✓	DN	WO 94/17038	08/04/94	PCT	C07D	205/12		
✓	DO	WO 94/20535	09/15/94	PCT	C07K	13/00		
✓	DP	WO 95/04533	02/16/95	PCT	A61K	31/445		
✓	DQ	WO 95/06470	03/09/95	PCT	A61K	31/435		
✓	DR	WO 95/08532	03/30/95	PCT	C07D	205/08		
✓	DS	WO 95/18143	07/6/95	PCT	C07J	71/00		
✓	DT	WO 95/26334	10/05/95	PCT	C07D	205/08		


S. L. V. O

10/10/03

RECEIVED

JAN 28 2003

TECH CENTER 1600/2900



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:  
CV01378KSERIAL NO.:  
10/057,534INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

APPLICANT:

Harry R. Davis et al.

FILING DATE:

January 25, 2002

GROUP:

1615

(Use several sheets if necessary)

✓	DU	WO 95/28919	11/02/95	PCT	A61K	31/19	X(abs.)	
	DV	WO 96/00288	01/04/96	PCT	C12N	15/12		
	DW	WO 96/09827	04/04/96	PCT	A61K	31/58		
	DX	WO 96/16037	05/30/96	PCT	C07D	205/08		
	DY	WO 96/19987	07/04/96	PCT	A61K	31/35		
✓	DZ	WO 96/40255	12/19/96	PCT	A61K	45/06		
	EA	WO 97/16455	05/09/97	PCT	C07H	3/04		
	EB	WO 97/18304	05/22/97	PCT	C12N	15/00		
	EC	WO 97/25042	07/17/97	PCT	A61K	31/42		
	ED	WO 97/28149	08/07/97	PCT	C07D	307/79		
✓	EE	WO 97/31907	09/04/97	PCT	C07D	263/56		
	EF	WO 97/35576	10/02/97	PCT	A61K	31/44		
	EG	WO 97/46238	12/11/97	PCT	A61K	31/245		
	EH	WO 98/01100	01/15/98	PCT	A61K			
	EI	WO 98/05331	02/12/98	PCT	A61K	31/45		
	EJ	WO 98/14179	04/09/98	PCT	A61K	9/50		
	EK	WO 98/31360	07/23/98	PCT	A61K	31/19		
	EL	WO 98/31361	07/23/98	PCT	A61K	31/215	X(abs.)	
	EM	WO 98/31366	07/23/98	PCT	A61K	31/445		
	EN	WO 98/43081	10/01/98	PCT	G01N	33/50		
	EO	WO 98/46215	10/22/98	PCT	A61K	9/20		
	EP	WO 98/47518	10/29/98	PCT	A61K	31/715		
	EQ	WO 98/57652	12/23/98	PCT	A61K	31/785		
	ER	WO 99/04815	04/02/99	PCT	A61K	45/00	X(abs.)	
	ES	WO 99/06035	02/11/99	PCT	A61K	31/00		
	ET	WO 99/06046	02/11/99	PCT	A61K	31/455		
	EU	WO 99/09967	03/04/99	PCT	A61K	31/00		
	EV	WO 99/12534	03/18/99	PCT	A61K	31/17	X(abs.)	
	EW	WO 99/11260	03/11/99	PCT	A61K	31/40		
	EX	WO 99/15159	04/01/99	PCT	A61K	31/00		
	EY	WO 99/15520	04/01/99	PCT	C07D	319/20	X(abs.)	
	EZ	WO 99/18072	04/15/99	PCT	C07D	205/08		
	FA	WO 99/20275	04/29/99	PCT	A61K	31/47		
	FB	WO 99/20614	04/29/99	PCT	C07D	265/36		
	FC	WO 99/29300	06/17/99	PCT	A61K	9/107		
	FD	WO 99/38498	08/05/99	PCT	A61K	31/00		
	FE	WO 99/38845	08/05/99	PCT	C07D	213/65		
	FF	WO 99/38850	08/05/99	PCT	C07D	237/32		
	FG	WO 99/46232	09/16/99	PCT	C07C	62/34	X(abs.)	
	FH	WO 99/47123	09/23/99	PCT	A61K	9/16		
	FI	WO 99/48488	09/30/99	PCT	A61K	31/00		
	FJ	WO 99/66929	12/29/99	PCT	A61K	31/405		
	FK	WO 99/66930	12/29/99	PCT	A61K	31/405		
	FL	WO 00/04011	01/27/00	PCT	C07D	319/06		
	FM	WO 00/07617	02/17/00	PCT	A61K	38/26		
✓	FN	WO 00/16749	03/30/00	PCT	A61K	9/16	X(abs.)	

RECEIVED

JAN 23 2003

TECH CENTER 1500/2900

S. V. 10/10/03

FORM 01-1449 <b>OFFICE</b> <b>JAN 21 2003</b> PATENT & TRADEMARK OFFICE		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV01378K		SERIAL NO.: 10/057,534	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT: Harry R. Davis et al.			
(Use several sheets if necessary)				FILING DATE: January 25, 2002		GROUP: 1615	
	FO	WO 00/18395	04/06/00	PCT	A61K	31/215	
	FP	WO 00/20623	04/13/00	PCT	C12P	41/00	
	FQ	WO 00/23415	04/27/00	PCT	C07C	69/734	
	FR	WO 00/23416	04/27/00	PCT	C07C	69/734	
	FS	WO 00/23425	04/27/00	PCT	C07D	209/80	
	FT	WO 00/23445	04/27/00	PCT	C07D	471/12	
	FU	WO 00/23451	04/27/00	PCT	C07D	487/14	
	FV	WO 00/28981	05/25/00	PCT	A61K	31/00	
	FW	WO 00/31548	06/02/00	PCT	G01N	33/68	
	FX	WO 00/32189	06/08/00	PCT	A61K	31/415	
	FY	WO 00/34240	06/15/00	PCT	C07D	205/08	
	FZ	WO 00/37057	06/29/00	PCT	A61K	9/48	
	GA	WO 00/37078	06/29/00	PCT	A61K	31/44	X(abs.)
	GB	WO 00/38721	07/06/00	PCT	A61K	45/06	
	GC	WO 00/38722	07/06/00	PCT	A61K	45/06	
	GD	WO 00/38723	07/06/00	PCT	A61K	45/06	
<i>SW</i>	GE	WO 00/38724	07/06/00	PCT	A61K	45/06	
<i>S. V. O</i>				DATE CONSIDERED <i>10/10/03</i>			

30599

RECEIVED  
 JAN 28 2003  
 TECH CENTER 1600/2900